Close
FINDING CURES TOGETHER<sup>SM</sup>

Media Advisories

 

 

Cancer Research Catalyst Blog: Epigenetics Research Collaboration, Newly Approved Breast Cancer Drug8313492/12/2015 7:25:28 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx22False2015-02-12T15:00:00Z<div class="ExternalClass37A12B63F6504D389359DDDE59F3E7A8"><p><em></em><a href="http&#58;//blog.aacr.org/" target="_blank"><em>Cancer Research Catalyst</em></a>, the blog of the American Association for Cancer Research (AACR), features a guest post from Peter A. Jones, PhD, DSc, research director and chief scientific officer at the Van Andel Research Institute, titled <a href="http&#58;//blog.aacr.org/vari-su2c-epigenetics-dream-team/" target="_blank">Harnessing Epigenetics and Collaboration to Positively Impact Patients</a>.</p><p>In addition, Karen Honey, PhD, senior managing editor of science communications at the AACR, discusses the latest U.S. Food and Drug Administration cancer drug approval—palbociclib (Ibrance)—in her post, <a href="http&#58;//blog.aacr.org/fda-approval-palbociclib/" target="_blank">Ongoing Progress Against Cancer&#58; New Breast Cancer Therapeutic Approved</a>. </p><p>These posts are part of the continuing mission of <em>Cancer Research Catalyst</em> to further accelerate the growth and spread of knowledge about cancer, while providing helpful and interesting information to AACR members and the public. </p><p><a href="http&#58;//blog.aacr.org/" target="_blank">Visit the blog</a> and subscribe. </p></div>
Cancer Research Catalyst Blog: A Look Ahead to 20157692591/27/2015 4:48:47 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx21False2015-01-27T17:00:00Z<div class="ExternalClass17A32793D33E40B9AFBA0AFBDF606C86"><p>​<em></em><a href="http&#58;//blog.aacr.org/" target="_blank">Cancer Research Catalyst</a>, the blog of the American Association for Cancer Research (AACR), features a new post, <a href="http&#58;//blog.aacr.org/experts-forecast-cancer-prevention-therapies-2015/" target="_blank">Experts Forecast Cancer Prevention and Therapies in 2015</a>, which discusses potential breakthroughs in cancer research expected in the upcoming year.</p><p>Srivani Ravoori, PhD, AACR senior science writer, interviewed three eminent AACR experts on promising cancer research areas—immunotherapy, cancer genomics, and cancer prevention—for this post.</p><p>These posts are part of the continuing mission of Cancer <em>Research Catalyst</em> to further accelerate the growth and spread of knowledge about cancer, while providing helpful and interesting information to AACR members and the public. </p><p>Visit the blog at <a href="http&#58;//blog.aacr.org/" target="_blank">http&#58;//blog.aacr.org</a> and subscribe. </p></div>
​Cancer Research Catalyst Blog Discusses Personalized Oncology and Cell Biology7240101/16/2015 4:41:46 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx20False2015-01-16T14:30:00Z<div class="ExternalClassB21EB1A296F044FBB67B18361B73715F"><p><em></em><a href="http&#58;//blog.aacr.org/" target="_blank">Cancer Research Catalyst</a>, the blog of the American Association for Cancer Research (AACR), features a guest post, “<a href="http&#58;//blog.aacr.org/plugging-cell-biology-genomic-world/" target="_blank">Plugging Cell Biology Into a Genomic World</a>,” about the integration of cell biology with genomics to enhance personalization of cancer treatment, from AACR member and cancer cell biologist Adam Marcus, PhD.</p><p>Marcus is also an associate professor at Emory University School of Medicine in Atlanta and director of a research laboratory at Winship Cancer Institute of Emory University focusing on cell biology and pharmacology in lung and breast cancers.</p><p>The post also includes Marcus’ recent TEDxPeachtree talk, “Every Cancer is Personal.”</p><p>These posts are part of the continuing mission of Cancer Research Catalyst to further accelerate the growth and spread of knowledge about cancer, while providing helpful and interesting information to AACR members and the public.</p><p><a href="http&#58;//blog.aacr.org/" target="_blank">Visit the blog</a> and subscribe. </p></div>
Cancer Research Catalyst Previews Ken Burns-produced PBS Documentary on Cancer6972271/9/2015 3:19:18 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx19False2015-01-09T14:00:00ZThree-part series slated to air March 30-April 1<div class="ExternalClass55BB0F748C114B209332BAB25F0F80FC"><p><em><a href="http&#58;//blog.aacr.org/" target="_blank">Cancer Research Catalyst</a></em>, the blog of the American Association for Cancer Research (AACR), features a <a href="http&#58;//blog.aacr.org/cancer-emperor-of-all-maladies-documentary/" target="_blank">post</a> on the making of the PBS documentary, <em>Cancer&#58; The Emperor of All Maladies</em> (the AACR is a supporter). Noted documentary filmmaker Ken Burns is the executive producer, co-writer, and senior creative consultant for the project, which is based on Siddhartha Mukherjee’s Pulitzer Prize-winning book, <em>The Emperor of All Maladies&#58; A Biography of Cancer</em>.</p><p>For <a href="http&#58;//blog.aacr.org/cancer-emperor-of-all-maladies-documentary/" target="_blank">this post</a>, Kevin McLaughlin, executive editor of the AACR’s <em><a href="http&#58;//www.cancertodaymag.org/Pages/default.aspx" target="_blank">Cancer Today</a></em>, discusses the making of this documentary. </p><p>These posts are part of the continuing mission of <em>Cancer Research Catalyst</em> to further accelerate the growth and spread of knowledge about cancer, while providing helpful and interesting information to AACR members and the public. </p><p><a href="http&#58;//blog.aacr.org/" target="_blank">Visit the blog</a> and subscribe. </p></div>
Molecular Targets and Cancer Therapeutics 26th EORTC-NCI-AACR Symposium49753811/13/2014 3:42:41 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx18False2014-11-13T14:00:00ZNov. 18-21, 2014; Barcelona, Spain<div class="ExternalClassE53098A8E36C4E229A63AD34F69BB3CE"><p>​<strong><em>Editor’s Note</em></strong><em>&#58; In a </em><a href="http&#58;//blog.aacr.org/qa-lee-helman-md-cancer-targets-therapeutics/" target="_blank"><em>post published today</em></a><em> on the AACR blog, </em><a href="http&#58;//blog.aacr.org/" target="_blank">Cancer Research Catalyst</a><em>, the National Cancer Institute’s Lee Helman, MD, co-chair of the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, discusses what to expect this year, and peers into the future of targeted cancer therapies and immunotherapy.</em></p><p>Journalists are invited to attend this meeting held by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI), and the American Association for Cancer Research (AACR). <a href="http&#58;//www.ecco-org.eu/Events/EORTC_NCI_AACR_2014/Media" target="_blank">Registration</a> is free for credentialed journalists. </p><p>The <a href="/Meetings/Pages/MeetingDetail.aspx?EventItemID=18">EORTC-NCI-AACR Symposium</a> is the premier scientific forum for researchers developing the cancer drugs of the future. Understanding the pathways and mechanisms that cause cancer and regulate the biological behavior of tumor cells has led to the development of numerous new agents, &quot;designer&quot; diagnostics, prognostic tests, &quot;smart&quot; drugs, innovative targets for clinical trials, and other new ways of tackling cancer. Around 2,200 international cancer experts will be attending the meeting to discuss the latest breakthroughs in preclinical and clinical research to facilitate further advances against cancer.</p><p>The majority of the abstracts are <a href="http&#58;//www.ecco-org.eu/ENA" target="_blank">available online</a>. Some, including late-breaking abstracts and those that form part of the official media program, will only be embargoed and published online on the day of presentation.</p><p>Examples of highlighted research include&#58; </p><ul><li>First report from a phase I clinical trial of a first-in-class drug, AG-120, in patients with advanced hematologic malignancies with the IDH1 mutation; </li><li>Updated interim results from the ongoing phase II clinical trial examining the potential of rociletinib, a new drug that targets mutant EGFR, including theT790M mutant, as a treatment for non-small cell lung cancer;</li><li>Early results of the safety and efficacy of ASP 8273, an inhibitor of mutant EGFR, including the T790M mutant;</li><li>Report on the safety and efficacy of a combination therapy (the BRAF V600 inhibitor encorafenib, the EGFR-targeted monoclonal antibody cetuximab, with or without the P13K inhibitor alpelisib) to treat patients with advanced colorectal cancer with the BRAF mutation; </li><li>Interim results from a phase II clinical trial testing a combination of bevacizumab and erlotinib as a treatment for metastatic papillary kidney cancer;</li><li> Preclinical science and updated results from ARMOR2, a phase II clinical trial testing galeterone in men with castration-resistant prostate cancer; and</li><li>Results from a phase I clinical trial pioneering a new approach to treating HPV-related cervical cancer.</li></ul><p>Sessions are open to journalists and registration information is <a href="http&#58;//www.ecco-org.eu/Events/EORTC_NCI_AACR_2014/Media" target="_blank">available online</a>.</p><p>A media center with international phone and internet connections will be available.</p><p>The official language of the symposium is English and all press materials will be in English.</p><p><strong>For media queries about the symposium, contact&#58; </strong></p><p>Emma Mason, media consultant<br><a href="mailto&#58;wordmason@mac.com">wordmason@mac.com</a> <br>+44 (0) 7711 296 986</p><p>Jeremy Moore, American Association for Cancer Research<br><a href="mailto&#58;jeremy.moore@aacr.org">jeremy.moore@aacr.org</a><br>267-250-5441</p><p><strong>Accommodations</strong></p><p>Get information on <a href="http&#58;//www.ecco-org.eu/Events/EORTC_NCI_AACR_2014/Travel-and-Accommodation" target="_blank">accommodations in Barcelona</a>.</p><p><a href="https&#58;//twitter.com/search?f=realtime&amp;q=%23ENA2014" target="_blank"><img class="ms-rte-paste-setimagesize" alt="Twitter" src="/PublishingImages/Twitter-bird-blue-on-white_50x50.jpg" style="margin&#58;5px;" /></a><a href="https&#58;//twitter.com/search?f=realtime&amp;q=%23ENA2014" target="_blank">#ENA2014</a></p></div>
2014 San Antonio Breast Cancer Symposium to Be Held Dec. 9-1345961311/3/2014 4:46:34 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx17False2014-11-03T14:00:00Z<div class="ExternalClass660DF9BD924342BB8B29D00A4573325F"><p>SAN ANTONIO — The American Association for Cancer Research, The Cancer Therapy &amp; Research Center at The University of Texas Health Sciences Center at San Antonio, and Baylor College of Medicine will be hosting the <a href="http&#58;//www.sabcs.org/" target="_blank">2014 San Antonio Breast Cancer Symposium</a>, Dec. 9–13, at the Henry B. Gonzalez Convention Center, San Antonio.</p><p>The symposium provides news on state-of-the-art breast cancer research, including experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease. </p><p><a href="http&#58;//www.sabcs.org/ProgramSchedule/index.asp" target="_blank">View</a> the scientific program.</p><p>Please note the 2014<strong> embargo policy</strong>&#58; All data at the 2014 San Antonio Breast Cancer Symposium lifts embargo at 8 a.m. CT, Dec. 9, with the exception of research being presented in the official press program, which is designated to lift at date and time of presentation during an official press conference.</p><p>Official press conferences will take place 7&#58;30 a.m. CT, Wednesday, Dec. 10; Thursday, Dec. 11; and Friday, Dec. 12.<br>A press kit containing releases and highlighted abstracts will be available in early December. </p><p>Registration will be available to members of the media who provide credentials. For more information or to register for the meeting, please contact Lauren Riley at <a href="mailto&#58;lauren.riley@aacr.org">lauren.riley@aacr.org</a> or 215-446-7155 or Jeremy Moore at <a href="mailto&#58;jeremy.moore@aacr.org">jeremy.moore@aacr.org</a> or 215-446-7109.</p><p><a href="https&#58;//twitter.com/search?f=realtime&amp;q=%23SABCS14" target="_blank"><img alt="Twitter bird" src="/PublishingImages/Twitter-bird-blue-on-white_50x50.jpg" style="margin&#58;5px;" /></a><a href="https&#58;//twitter.com/search?f=realtime&amp;q=%23SABCS14" target="_blank">#SABCS14</a></p></div>
​Cancer Health Disparities Conference Set for Nov. 9-12 in San Antonio45077310/30/2014 1:26:18 PM4http://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx16False2014-10-30T13:00:00Z<div class="ExternalClass4BD48B04155A45DCBCB0CA4C2643B74D"><p>SAN ANTONIO — The American Association for Cancer Research (AACR) will release new research on disparities in cancer that represent a major public health problem at its conference on <a href="/Meetings/Pages/MeetingDetail.aspx?EventItemID=23">The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medical Underserved</a>, Nov. 9-12 at the Grand Hyatt San Antonio.</p><p>A press kit containing releases and highlighted abstracts will be available Monday, Nov. 3. Research that will be highlighted in the conference includes&#58;</p><ul><li>Methods for increasing clinical trial enrollment among Latina women with breast cancer;</li><li>Survival rates among American Native and Alaskan Indian populations;</li><li>Factors that influence breast cancer risk among women of Mexican descent; and</li><li>Disparities in human papillomavirus vaccination rates.</li></ul><p>&#160;</p><p>In addition, John D. Carpten, PhD, deputy director of basic sciences at the Translational Genomics Research Institute in Phoenix, will deliver the 2014 AACR Distinguished Lectureship on the Science of Cancer Health Disparities, funded by Susan G. Komen.</p><p><a href="/Meetings/Pages/Program-Detail.aspx?EventItemID=23&amp;ItemID=48&amp;DetailItemID=">Read</a> the online program.</p><p>For more information or to register for the meeting, please contact Lauren Riley at <a href="mailto&#58;lauren.riley@aacr.org">lauren.riley@aacr.org</a> or 215-446-7155, or Jeremy Moore at <a href="mailto&#58;jeremy.moore@aacr.org">jeremy.moore@aacr.org</a> or 215-446-7109. </p><p><a href="https&#58;//twitter.com/search?f=realtime&amp;q=AACRDisp14" target="_blank"><img alt="Twitter" src="/PublishingImages/Twitter-bird-blue-on-white_50x50.jpg" style="margin&#58;5px;" /></a>&#160;<a href="https&#58;//twitter.com/search?f=realtime&amp;q=AACRDisp14" target="_blank">#AACRDisp14</a></p></div>
Cancer Research Catalyst features informative posts on cancer prevention for media41918410/20/2014 4:35:46 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx15False2014-10-20T16:30:00Z<div class="ExternalClass252F1E5981D24F83B09DDE238C5074DF"><p><em></em><a href="http&#58;//blog.aacr.org/" target="_blank">Cancer Research Catalyst</a>, the blog of the American Association for Cancer Research (AACR), features two recent posts on cancer prevention research that you might find interesting and informative. </p><p>Graham A. Colditz, MD, DrPH, Niess-Gain Professor of Surgery, professor of medicine, and associate director of prevention and control at the Alvin J. Siteman Cancer Center at the Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, provides a <a href="http&#58;//blog.aacr.org/youthful-approach-expanding-reach-breast-cancer-prevention/" target="_blank">guest post</a> on breast cancer prevention. Colditz, who recently received the <a href="/Newsroom/Pages/News-Release-Detail.aspx?ItemID=607">2014 AACR Award for Outstanding Achievement in Cancer Prevention Research</a>, stresses the importance of early breast cancer prevention beginning in childhood.</p><p>On the opposite spectrum, Robert L. Strausberg, PhD, executive director of collaborative sciences at the Ludwig Institute for Cancer Research, <a href="http&#58;//blog.aacr.org/addressing-cancer-graying-america/" target="_blank">discusses</a> cancer prevention among the United States’ aging population, a demographic that is growing as life expectancies increase.</p><p>These posts are part of the continuing mission of <em>Cancer Research Catalyst</em> to further accelerate the growth and spread of knowledge about cancer, while providing helpful and interesting information to our members and the public. </p><p><a href="http&#58;//blog.aacr.org/" target="_blank">Visit the blog</a> and subscribe. </p></div>
2014 Turning the Tide Against Cancer National Conference Will Explore Policy Solutions to Pressing Challenges in Oncology37944010/6/2014 4:48:59 PM3http://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx13False2014-10-06T13:00:00ZNational conference to address how public policy can sustain innovation to turn the tide against cancer<div class="ExternalClassB16733CB116F4AB0B16EDA8BE610788D"><p>The Personalized Medicine Coalition, the American Association for Cancer Research, and Feinstein Kean Healthcare are convening the second national <a href="http&#58;//turningthetideagainstcancer.org/" target="_blank">Turning the Tide Against Cancer Through Sustained Medical Innovation</a> conference to continue the ongoing dialogue around policy solutions that align with scientific advances and support innovation in cancer research and care, while addressing the issue of rising health care costs.</p><p>The conference will bring together leaders from across the scientific, clinical, regulatory, industry, and patient communities to discuss actionable policies that support the shift to patient-centric cancer research and care and address issues of value and cost in oncology. The policy options discussed at the conference will inform the ongoing activities of the Turning the Tide Against Cancer initiative to ensure that future investments in research and care delivery will address the evolving demands of the cancer community.</p><p dir="ltr" style="margin-right&#58;0px;"><strong>WHEN</strong>&#58;&#160;<br>Thursday, Oct. 9, 2014<br>8&#58;30 a.m. – 4 p.m. EDT</p><p><strong>LOCATION</strong>&#58;&#160;<br>Knight Conference Center at the Newseum <br>555 Pennsylvania Ave., NW<br>Washington, DC&#160; 20001</p><p><strong>TWITTER</strong>&#58; &#160;<br><a href="https&#58;//twitter.com/search?f=realtime&amp;q=%23T3cancer" target="_blank">#T3cancer</a></p><p><strong>REGISTRATION INFORMATION</strong>&#58; <br>Registration for members of the media is free. Please <a href="mailto&#58;amanda.guisbond@fkhealth.com" target="_blank">email</a> or call Amanda Guisbond (617-761-6797) for press credentials.&#160; </p><p><strong>SPEAKERS</strong>&#58;</p><ul><li><strong>Amy Abernethy, MD, PhD</strong>, professor of medicine, Duke University School of Medicine; chief medical officer and senior vice president of oncology, Flatiron Health Inc.;</li><li><strong>Anna Barker, PhD</strong>, co-director, Complex Adaptive Systems Initiative; president and director, National Biomarker Development Alliance; professor, School of Life Sciences, Arizona State University;</li><li><strong>Tanisha V. Carino, PhD</strong>, executive vice president, Avalere Health;</li><li><strong>John J. Castellani</strong>, president and chief executive officer, Pharmaceutical Research and Manufacturers of America; </li><li><strong>Tony Coelho</strong>, former member, U.S. House of Representatives; chairman, Partnership to Improve Patient Care;</li><li><strong>Newton F. Crenshaw</strong>, vice president, North American Oncology Commercial Operations, Global Business Development, and Advocacy,&#160; Eli Lilly and Company;</li><li><strong>William S. Dalton, PhD, MD</strong>, chief executive officer, M2Gen; director, DeBartolo Family Personalized Medicine Institute, H. Lee Moffitt Cancer Center and Research Institute; </li><li><strong>Stephen L. Eck, MD, PhD</strong>, vice president, global head of oncology medical sciences, Astellas Pharma Global Development;</li><li><strong>Shelley Fuld Nasso, MPP</strong>, chief executive officer, National Coalition for Cancer Survivorship;</li><li><strong>Patricia J. Goldsmith</strong>, chief executive officer, CancerCare;</li><li><strong>Roy S. Herbst, MD, PhD</strong>, ensign professor of medicine, professor of pharmacology, chief of medical oncology, director of the Thoracic Oncology Research Program, and associate director for translational research, Yale Comprehensive Cancer Center and Yale School of Medicine;</li><li><strong>Linda House, RN, BSN, MSM</strong>, executive vice president, external affairs, Cancer Support Community;</li><li><strong>Robert J. Hugin</strong>, chairman and chief executive officer, Celgene Corporation;</li><li><strong>Suleika Jaouad</strong>, <em>The New York Times </em>Emmy<sup>®</sup> Award-winning columnist, “Life, Interrupted,” and cancer survivor;</li><li><strong>Paul G. Kluetz, MD</strong>, acting deputy office director, prostate cancer scientific liaison, Office of Hematology and Oncology Products, U.S. Food and Drug Administration;</li><li><strong>Michael Kolodziej, MD</strong>, national medical director, oncology solutions, office of the chief medical officer, Aetna;</li><li><strong>Jennifer Malin, MD, PhD</strong>, medical director for oncology for care management, WellPoint Inc.;</li><li><strong>Lee N. Newcomer, MD, MHA</strong>, senior vice president, oncology, genetics, and women’s health, UnitedHealthcare; </li><li><strong>Richard L. Schilsky, MD, FASCO</strong>, chief medical officer, American Society of Clinical Oncology; professor emeritus, University of Chicago;</li><li><strong>Lowell Schnipper, MD</strong>, Theodore W. and Evelyn G. Berenson professor, Department of Medicine, Harvard Medical School; chief, hematology/oncology, Beth Israel Deaconess Medical Center; clinical director, Beth Israel Deaconess Medical Center Cancer Center; and</li><li><strong>Jeff A. Walker, MBA</strong>, senior executive director for administration, Comprehensive Cancer Center and James Cancer Hospital/Solove Research Institute, The Ohio State University.</li></ul><p>&#160;</p><p><a href="http&#58;//www.turningthetideagainstcancer.org/" target="_blank">View</a> the full agenda. </p></div>
Cancer Research Catalyst features informative posts for media36672810/1/2014 1:17:12 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx12False2014-10-01T13:00:00Z<div class="ExternalClass23DC7DB06E1446C79B2A797FC9C28A75"><p><a href="http&#58;//blog.aacr.org/" target="_blank"><em>Cancer Research Catalyst</em></a>, the blog of the American Association for Cancer Research (AACR), features two recent posts on lung cancer research that you might find interesting and informative. </p><p>Fadlo R. Khuri, MD, deputy director for the Winship Cancer Institute of Emory University in Atlanta, provides a <a href="http&#58;//blog.aacr.org/lung-cancer-progress-made-yet/" target="_blank">guest post</a> on lung cancer research, highlighting the progress already made and the needs for the future, including an enhanced understanding of lung cancer origins in never-smokers and implementation of strong tobacco control programs.</p><p>Srivani Ravoori, PhD, AACR senior science writer, <a href="http&#58;//blog.aacr.org/findings-open-doors-rational-lung-cancer-treatment-strategies/" target="_blank">discusses</a> new findings on mutations and drug resistance that could lead to new treatment strategies for certain lung cancer patients. </p><p>These posts are part of the continuing mission of <em>Cancer Research Catalyst</em> to further accelerate the growth and spread of knowledge about cancer, while providing helpful and interesting information to our members and the public. </p><p><a href="http&#58;//blog.aacr.org/" target="_blank">Visit</a> the blog and subscribe. </p></div>